Form 4: Aura Biosciences Executive Conor Kilroy Reports Stock and Option Transactions
SEC Form 4 Filing
Conor Kilroy, Chief Legal Officer and Secretary of Aura Biosciences, reports acquisition of stock and options.
Summary
- On February 3, 2025, Conor Kilroy, Chief Legal Officer and Secretary of Aura Biosciences, reported transactions involving the company's stock.
- Kilroy acquired 90,475 shares of common stock through a restricted stock unit (RSU) award under the Issuer's 2021 Stock Option and Incentive Plan.
- Each RSU represents the right to receive one share of Aura Biosciences' Common Stock.
- These RSUs vest in four substantially equal annual installments beginning on February 15, 2026, subject to continued service.
- Kilroy also acquired options to buy 59,525 shares of common stock at an exercise price of $7.68.
- 25% of the shares underlying the option vest on February 3, 2026, with the remainder vesting pro-rata in 36 monthly installments, subject to continued service.
- Following these transactions, Kilroy directly owns 186,475 shares of common stock and options for 59,525 shares.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard regulatory filing reflecting compensation and insider transactions. The vesting schedules suggest a positive outlook for the company's future.
Positives
- The RSU award and option grant suggest confidence in the company's future performance.
- The vesting schedules incentivize continued service by the executive.
Future Outlook
The vesting schedules for the RSUs and stock options suggest a long-term commitment from the executive.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's sentiment towards the company's prospects.
Comparison to Industry Standards
- Stock option and RSU grants are common forms of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
- Vesting schedules are typically structured to incentivize long-term performance and retention, often over a period of 3-4 years.
Stakeholder Impact
- Shareholders can use this information to assess management's alignment with their interests.
- Employees may view this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of transaction for stock and option acquisition |
| 02/03/2025 | Date of option grant |
| 02/15/2026 | First vesting date for RSUs |
| 02/03/2026 | First vesting date for 25% of the options |
| 02/02/2035 | Expiration date for the stock options |
| 02/04/2025 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.